Persoulla Nicolaou

Dr. Persoulla Nicolaou

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2018 in Autophagy
Verified
Journal Article
Closed access
GLGuan-Sheng Liu
Guan-Sheng Liu
HZHongyan Zhu
Hongyan Zhu
WCWen-Feng Cai
Wen-Feng Cai
XWXiaohong Wang
Xiaohong Wang
MJMin Jiang
Min Jiang
EKEvangelia G. Kranias
Evangelia G. Kranias
HSPB6/Hsp20 (heat shock protein family B [small] member 6) has emerged as a novel cardioprotector against stress-induced injury. We identified a human mutant of HSPB6 (HSPB6S10F) exclusively present in dilated cardiomyopathy (DCM) patients. Cardiac expression of this mutant in mouse hearts resulted in remodeling and dysfunction, which progressed to heart failure and early death. These detrimental effects were associated with reduced interaction of mutant HSPB6S10F with BECN1/Beclin 1, leading to BECN1 ubiquitination and its proteosomal degradation. As a result, autophagy flux was substantially inhibited and apoptosis was increased in HSPB6S10F-mutant hearts. In contrast, overexpression of wild-type HSPB6 (HSPB6 WT) not only increased BECN1 levels, but also competitively suppressed binding of BECN1 to BCL2, resulting in stimulated autophagy. Indeed, preinhibition of autophagy attenuated the cardioprotective effects of HSPB6 WT. Taken together, these findings reveal a new regulatory mechanism of HSPB6 in cell survival through its interaction with BECN1. Furthermore, Ser10 appears to be crucial for the protective effects of HSPB6 and transversion of this amino acid to Phe contributes to cardiomyopathy.

2 December 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TPTracy J. Pritchard
Tracy J. Pritchard
YKYoshiaki Kawase
Yoshiaki Kawase
KHKobra Haghighi
Kobra Haghighi
AAAhmad Anjak
Ahmad Anjak
WCWenfeng Cai
Wenfeng Cai
EKEvangelia G. Kranias
Evangelia G. Kranias
Impaired sarcoplasmic reticulum calcium cycling and depressed contractility are key characteristics in heart failure. Defects in sarcoplasmic reticulum function are characterized by decreased SERCA2a Ca-transport that is partially attributable to dephosphorylation of its regulator phospholamban by increased protein phosphatase 1 activity. Inhibition of protein phosphatase 1 through activation of its endogenous inhibitor-1 has been shown to enhance cardiac Ca-handling and contractility as well as protect from pathological stress remodeling in young mice. In this study, we assessed the long-term effects of inducible expression of constitutively active inhibitor-1 in the adult heart and followed function and remodeling through the aging process, up to 20 months. Mice with inhibitor-1 had normal survival and similar function to WTs. There was no overt remodeling as evidenced by measures of left ventricular end-systolic and diastolic diameters and posterior wall dimensions, heart weight to tibia length ratio, and histology. Higher phosphorylation of phospholamban at both Ser16 and Thr17 was maintained in aged hearts with active inhibitor-1, potentially offsetting the effects of elevated Ser2815-phosphorylation in ryanodine receptor, as there were no increases in arrhythmias under stress conditions in 20-month old mice. Furthermore, long-term expression of active inhibitor-1 via recombinant adeno-associated virus type 9 gene transfer in rats with pressure-overload induced heart failure improved function and prevented remodeling, associated with increased phosphorylation of phospholamban at Ser16 and Thr17. Thus, chronic inhibition of protein phosphatase 1, through increases in active inhibitor-1, does not accelerate age-related cardiomyopathy and gene transfer of this molecule in vivo improves function and halts remodeling in the long term.

1 September 2020 in Advances in Physiology Education
Verified
Journal Article
Closed access
PDF file
Persoulla NicolaouPersoulla Nicolaou
Persoulla Nicolaou
MSMamoun El Saifi
Mamoun El Saifi
To reduce medication errors, medical educators must nurture the early development of rational and safe prescribing. Teaching pharmacology is challenging because it requires knowledge integration across disciplines, including physiology and pathology. Traditionally, pharmacology has been taught using lecture-based learning, which conveys consistent information but may promote passive learning. Virtual patients (VPs) have been used more recently to promote active learning, mainly in clinical years. Conversely, the use of VPs in preclinical disciplines, including pharmacology, is not well described. The objective was to investigate the potential benefits of combining traditional teaching with VPs in preclinical pharmacology teaching. All year 3 medical students (2 cohorts), enrolled in the Systematic Pharmacology I course (lectures: 3 h weekly; tutorial: 1 h weekly), were invited to participate in this naturalistic, prospective study. During tutorials, students were taught using case-based discussion and single-best-answer questions (control) in four tutorials and VPs (experimental) in the remaining six tutorials. The impact of VPs was assessed by 1) performance in written examinations, and 2) student satisfaction/perceptions, using a validated, modified questionnaire. Examination performance related to teaching in VP-based tutorials was significantly improved, compared with traditional tutorials. The level of difficulty of control and experimental assessment items was comparable, as determined by the Angoff method. Facilitation of learning was higher in VP tutorials, while a no-harm effect was noted on knowledge acquisition/maintenance, authenticity of learning, and disadvantages of learning. VPs may be effectively integrated in preclinical pharmacology teaching, with benefits on pharmacological knowledge and facilitation of learning.

1 April 2021 in European Journal of Pharmacology
Verified
Journal Article
Closed access
Persoulla NicolaouPersoulla Nicolaou
Persoulla Nicolaou

3 January 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
RAReem Faris Aazar
Reem Faris Aazar
RARayan Arzouni
Rayan Arzouni
Persoulla NicolaouPersoulla Nicolaou
Persoulla Nicolaou
Overactivation of the renin–angiotensin–aldosterone system (RAAS) promotes haemodynamic overload, inflammation, and fibrosis in the heart and kidneys. Recently, sodium–glucose cotransporter-2 (SGLT2) inhibitors have emerged as a cornerstone therapy in cardiorenal protection. Emerging data indicate that adding SGLT2 inhibitors to angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, or angiotensin receptor–neprilysin inhibitors confers additional cardiorenal protection, yet their mechanistic basis and optimal clinical use in cardiovascular (CV) disease remain unclear. This review will integrate pre-clinical and clinical evidence on dual RAAS/SGLT2 modulation in CV disease, providing mechanistic insight into dual therapy. The review will finally outline priorities for future translational and outcome studies. Clinically, adding SGLT2 inhibitors to RAAS-based therapy reduces heart failure hospitalizations and slows kidney disease progression without new safety liabilities in type 2 diabetes, heart failure, and chronic kidney disease. Mechanistically, SGLT2 inhibition restores tubuloglomerular feedback and constricts the afferent arteriole; RAAS blockade dilates the efferent arteriole, and together, they lower intraglomerular pressure. Both classes also reduce oxidative stress, inflammatory signalling, and pro-fibrotic pathways, with SGLT2 inhibitors in several settings shifting RAAS balance toward the protective ACE2/angiotensin-(1–7)/Mas receptor axis. Key gaps include the scarcity of adequately powered trials designed to test combination therapy versus either component alone, limited evidence on timing and sequencing, incomplete characterization in high-risk groups, and mechanistic insight limited by study design in animal and cell models. Collectively, current data support layering SGLT2 inhibitors onto RAAS-based therapy, while definitive evidence from dedicated clinical trials is awaited.

26 April 2025 in BMC Medical Education
Verified
Journal Article
Open access
PDF file
DAD Avraam
D Avraam
ITI Televantou
I Televantou
AAAP Albert
AP Albert
AHAw Hitchings
Aw Hitchings
SNSa Nicolaou
Sa Nicolaou
Persoulla NicolaouPersoulla Nicolaou
Persoulla Nicolaou
Problem-based learning (PBL) is expected to encourage a deep learning approach. Whether this is realised in practice remains uncertain. We investigated the relationships between learning approaches, academic achievement and student satisfaction in an integrated PBL curriculum, among students with diverse characteristics. All Year 1 students of an undergraduate UK medical programme, delivered concurrently at City St George’s, University of London and the University of Nicosia, were invited to participate in 2019–2020 and 2020–2021. Students completed the validated Study Process Questionnaire (SPQ) at the beginning and end of Year 1. We explored changes in learning approaches and the associations of the learning approach with academic performance (in written and clinical examinations) and student satisfaction. 129 students participated. Deep motivation decreased significantly over the year [Baseline: 11.03 ± 2.29; End of Year 1: 10.21 ± 2.26; p < 0.05). Graphical representations and tertile analysis further showed changes in individual learning approaches. Lower deep motivation scores were observed among male students, and those who were older, white, held biomedical sciences degrees, undergraduate degrees, or were native English speakers. Conversely, higher surface motivation was seen among female students, and those who were younger or held undergraduate degrees. Nicosia students became less strategic by the end of the year. No association was found between learning approach, or its change within the year, and examination performance. However, surface learning was negatively correlated with satisfaction regarding aspects of pharmacology learning in PBL and prescribing confidence. Strategic learners preferred lectures and had mixed perceptions about learning pharmacology in PBL, although they found student diversity facilitated their learning. While PBL is expected to promote deep learning, our findings show that in a real-world context, these benefits are not consistently realised. Learners adopted less favourable learning approaches over the year, with increasing reliance on surface learning and less deep motivation. Such shifts may be due to excessive workload, assessment burden or curriculum uncertainty. We have identified student groups that may be more vulnerable to the stresses of a PBL setting, which may represent targets for intervention. Future studies may also investigate curriculum adaptations to enhance deep learning in a PBL curriculum.